● Covered by 1 source · 1 reportMedium impact1 neutral
Intero Biosystems develops human intestinal organoids for drug testing, reducing animal reliance
Key points
- Intero Biosystems creates human intestinal organoids for drug testing.
- Organoids mimic human gut with multiple cell types.
- Aims to reduce reliance on animal testing in drug development.
- Raised $2.3 million pre-seed, generated over $400,000 revenue.
- Sells organoids, supplies, and offers custom lab testing services.
Human Intestinal Organoids for Drug Development
Intero Biosystems, a startup based in Denver, is developing human intestinal organoids, which are lab-grown tissues designed to mimic the human gut. These organoids are intended for use by pharmaceutical, biotech, food, and chemical companies to test drugs and other compounds. The goal is to provide a more accurate model for studying how substances affect the human body before clinical trials, addressing limitations of traditional animal models.
Addressing Limitations of Animal Models
Drug development has historically relied on animal models, but species differences often lead to discrepancies in how drugs affect animals versus humans, contributing to high failure rates in clinical trials. Intero's organoids contain multiple cell and tissue types found in the human intestine, which the company states makes them a more human-relevant model compared to simpler in-vitro systems. This approach seeks to supplement and potentially reduce the need for animal testing.
Product Offerings and Services
Intero's flagship product, GastroScreen, consists of human intestinal organoids, each approximately 1 millimeter in size, shipped in batches of about 100. Customers can use these organoids as healthy models or induce disease-like conditions for testing. Beyond the organoids, Intero also sells necessary supplies, such as nutrient mixes and experimental chemicals. The company provides custom lab testing services, including experimental design, lab work, and data delivery, focusing on drug safety and disease research.
Company Growth and Funding
Founded in 2024 as a spin-off from the University of Michigan, Intero Biosystems currently has seven employees and serves just under 10 customers. The startup secured a $2.3 million pre-seed funding round last year. From the fourth quarter of last year through the third quarter of this year, Intero generated over $400,000 in revenue.
✨ This summary was generated by AI from the outlets' reporting listed below. It is not independently verified and may contain errors — check the original sources. How BrevFeed works →
The daily brief
One email each morning: the day's tech stories, clustered across outlets and summarized. No account needed.
One email a day. Unsubscribe in one click, any time.
Today's brief
Spend a few minutes, get the whole day. Every topic's top stories in one hands-free rundown — listen, watch, or read the transcript.
▶ Play today's brief
New every morning, and the back catalogue is archived by date.
Reporting from
Intero Biosystems, a Denver-based startup, is developing and selling human intestinal organoids, lab-grown tissue that mimics the gut, to pharmaceutical and biotech companies. These organoids serve as a model for testing drugs and compounds, aiming to provide more human-relevant data and reduce reliance on animal testing in drug development. The company has raised $2.3 million in pre-seed funding and generated over $400,000 in revenue.